Here's Why Repligen (RGEN) is a Strong Growth Stock

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores categorize stocks into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score identifies undervalued stocks using financial ratios [3] - Growth Score emphasizes companies with strong financial health and growth potential [4] - Momentum Score targets stocks with favorable price trends [5] - VGM Score combines all three styles to provide a comprehensive assessment of stocks [6] Zacks Rank and Style Scores Interaction - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investment decisions, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.62% since 1988 [7] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [9] - Stocks with lower ranks, even with good Style Scores, may still face downward price pressure due to negative earnings forecasts [10] Company Spotlight: Repligen Corporation - Repligen Corporation, based in Waltham, MA, specializes in advanced bioprocessing technologies for biopharmaceutical manufacturing [11] - The company holds a Zacks Rank of 2 (Buy) and a VGM Score of B, indicating strong potential [11] - Repligen is projected to achieve year-over-year earnings growth of 6.3% for the current fiscal year, with an upward revision in earnings estimates [12] - The Zacks Consensus Estimate for Repligen's earnings is $1.68 per share, with an average earnings surprise of +11.3% [12]